-
How we can target the underlying immune processes in pathological inflammation in obesity, cancer and liver disease.(Post)
Dr. Melissa Conroy, TTMI I am an immunologist and senior research fellow in the Cancer Immunology and Immunotherapy Group, Department of Surgery at Trinity
Tunel 1-Step Assay Kits(Page)TUNEL Assay Kits | 1-Step In Situ Apoptosis Detection | Assay Genie
Macrophage Activation: A Keystone in Immune Response and Therapeutic Potential(Post)In the intricate tapestry of the immune system, macrophages play a pivotal role, orchestrating a wide range of biological responses that protect the body against pathogens, remove cellular debris,
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
Christmas Lab Party Competition | Assay Genie(Post)We know it gets tiring being in the lab every day, especially with the evenings getting darker and gloomier. So, to get you in the festive spirit, we're holding a competition to win money to th
Fenofibrate Usage for Diabetes Damage(Post)Fenofibrate, also known as FEN, is a drug that is used to lower cholesterol levels. It works by blocking the absorption of dietary cholesterol in the small intestine and therefore, red
Toll-Like Receptor (TLR) & Innate Sensing(Page) Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
How does Acute Myeloid Leukaemia start?(Post)I have been in the situation that I’m sure many of us have. I work on genes, which if you name to any right-minded individual, sound like a random string of nonsensical gibberish. So, maybe
The Complement Cascade and Its Regulators(Page) Key Players in T Cell Regulation: Lag-3, Tim-3, and TIGIT(Post)Understanding Lag-3, Tim-3, and TIGIT: Key Players in T Cell RegulationThe immune system's ability to regulate T cell responses is crucial for maintaining homeostasis and combating diseases such as ca
CD8+ T Cells: Understanding the Role of Cytotoxic T Cells in Immunity(Post)Immunology · T LymphocytesCD8+ T Cells: Cytotoxic Mechanisms, Memory and ExhaustionCD8+ T cells kill infected and transformed cells directly, and they do it with a specificity nothing else in the immu
Unlocking the Fortress: CAR-T Cell Therapy's Next Frontier in Solid Tumors(Post)For years, the success of CAR-T cell therapy has been a beacon of hope in the fight against blood cancers, offering remarkable remissions where other treatments have failed. Yet, solid tumors—the form
Turning Tumors Against Themselves: In Vivo Reprogramming of Cancer Cells into Dendritic Sentinels(Post)Imagine a future where cancer cells, once masters of disguise, are forced to reveal themselves and even train the body's immune system to fight back. This isn't science fiction; it's the groundbreaki
TLR Innate Sensing Pathway: Receptors, MyD88/TRIF and Assays(Post)Toll-like receptors are the reason a milligram of endotoxin can kill a mouse. They are the fastest, least discriminating layer of immunity: germline-encoded sensors that read conserved microbial chem
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune